Urology Annals
About UA | Search | Ahead of print | Current Issue | Archives | Instructions | Online submissionLogin 
Urology Annals
  Editorial Board | Subscribe | Advertise | Contact
Users Online: 439   Home Print this page  Email this page Small font size Default font size Increase font size
Year : 2020  |  Volume : 12  |  Issue : 1  |  Page : 37-41

The safety of ureteral stenting with the use of potassium citrate for management of renal uric acid stones

1 Department of Urology, Centre Perpignan Hospital, Perpignan, France
2 Department of Urology, Menoufia University, Al Minufiyah, Egypt

Correspondence Address:
Dr. Nawaf Abdulaziz Alenezi
Centre Perpignan Hospital, 20 Avenue du Languedoc, 66000 Perpignan
Login to access the Email id

DOI: 10.4103/UA.UA_60_19

PMID: 32015615

Rights and Permissions

Objectives: The objective is to evaluate the relative risks of ureteric stents application while managing uric acid stones with potassium citrate in terms of stone encrustations and urinary tract infection (UTI). Patients and Methods: We prospectively enrolled patients with renal uric acid stones who received K citrate from 2013 to 2018. Patient's demographics were collected. All patients were evaluated using noncontrast computed tomography (CT) scan to measure the stone size and density. JJ ureteric stent was inserted prior to the initiation of treatment. At follow-up, all patients underwent urine analysis for pH and to detect UTI. CT was repeated at 1 month and those patients who showed incomplete stone resolution underwent another course of treatment for another month. CT was repeated prior to stent removal. The presence of encrustations was inspected and collected. Results: We collected 59 patients with a median age of 36 years (18–73) and median stone burden of 26 mm3 (15–50). The median stone density was 310 HU (175–498). Twenty-one patients (35.6%) received K citrate treatment for 1-month, while the remaining patients had 2 months treatment. Sixteen patients (27.1%) had a complete stone dissolution, 41 patients (69.5%) had more than 50% decrease of stone burden while only 2 patients (3.4%) had stones with poor dissolution. Four patients (6.8%) experienced UTI while 2 patients (3.4%) had visible JJ encrustations. Most of these complications occurred when the treatment was offered for the 2nd month. Conclusion: Short-term use of ureteral stents is safe during the management of uric acid stones with K citrate.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded51    
    Comments [Add]    

Recommend this journal